IPP Bureau
Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
By IPP Bureau - June 19, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Lupin launches Thiamine Hydrochloride Injection USP in the US
By IPP Bureau - June 19, 2023
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Lupin receives EIR from FDA for its API manufacturing facility in Vizag
By IPP Bureau - June 19, 2023
The inspection closed with the facility receiving an inspection classification of NAI
Merck completes acquisition of Prometheus Biosciences
By IPP Bureau - June 17, 2023
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ
By IPP Bureau - June 17, 2023
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Health Ministry to prepare National Action Plan on AMR 2.0
By IPP Bureau - June 17, 2023
Convergent action on AMR identified as an important area of intervention
MoS Health addresses TB Health Technologies workshop
By IPP Bureau - June 17, 2023
Urges Innovators to produce quality products that can be deployed at scale
USFDA completes inspection at Dr Reddy's Laboratories' Bollaram API unit
By IPP Bureau - June 17, 2023
The inspection closed with zero observations
Briefs: Natco Pharma and Panacea Biotec
By IPP Bureau - June 16, 2023
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Bliss GVS Pharma updates on inspection by USFDA
By IPP Bureau - June 16, 2023
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Ipca Laboratories gets Form 483 for API manufacturing facility at Ratlam
By IPP Bureau - June 16, 2023
The company will submit its comprehensive response on these observations to the US FDA
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
By IPP Bureau - June 16, 2023
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
SMi discloses £6 million seed funding round, bolsters team with new C-suite hire
By IPP Bureau - June 15, 2023
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Airnov to showcase HDPE bottle range at upcoming CPHI China
By IPP Bureau - June 15, 2023
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Philips' direct-to-angio stroke pathway demonstrates improved patient outcomes
By IPP Bureau - June 15, 2023
Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient
